Please assess the completion status of the following clinical trial:

Trial Title: A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male; 12-65 years of age~* Subjects with severe hemophilia A~* Previously treated with factor VIII for a minimum of 150 exposure days~Exclusion Criteria:~* Inhibitors to FVIII (current evidence or history)~* Any other inherited or acquired bleeding disorder in addition to Hemophilia A~* Platelet count \< 100,000/mm3~* Creatinine \> 2x upper limit of normal or AST/ALT (aspartate aminotransferase/alanine aminotransferase) \> 5x upper limit of normal

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): On-demand treatment of BAY94-9027 at individual dose and number of infusions based upon location and severity of bleeds
- Arm 2 (Type: EXPERIMENTAL): Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by 2 infusions per week over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
- Arm 3 (Type: EXPERIMENTAL): Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by infusion every 5 days over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
- Arm 4 (Type: EXPERIMENTAL): Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by infusion every 7 days over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED

Based on this trial design, predict the completion outcome and termination type (if applicable).